BUDESONIDE / FORMOTEROL (DuoResp Spiromax®)

Clinical Indication

Asthma & COPD

Comments

For adults 18 years and over. No new initiations. Continued prescribing for established, well controlled patients only.

Must be used regularly for maximum benefit; twice a day dosing. The 160/4.5 strength is licensed to be prescribed as maintenance and reliever therapy (MART).

LLR Adult Asthma Guideline (≥18 years) AIR and MART FAQ

The LLR COPD guidelines have been updated (June 2026) and ICS/LABA combinations are no longer routinely recommended as a treatment option. No NEW initiations. For patients established on this therapy, treatment should be reviewed on a case-by-case basis, taking into account clinical stability and patient preference. Ongoing prescribing should be in line with the updated COPD guidelines.

Date of classification

June 2015